he world of gene therapy is booming and this success is being seen in neurology with multiple approvals
already this year such as AveXis’ recent SMA therapy.
GTxN (Gene Therapy for Neurological Disorders) is being developed to capture the exponential excitement and innovation in this field and has been built specifically for drug developers in an industry-focused format.
Watch this space and don’t miss the opportunity to attend GTxN this December and overcome your translational challenges so you don’t lose the race in bringing your gene therapy to market.
Join 60+ of your peers at this definitive conference over 3 days, 2 interactive workshops, 6+ hours of dedicated networking time and 18 expert industry presentations to accelerate the development of your gene therapy candidate for neurological disorders.
“I was impressed by many of the speakers and learnt a significant amount, which I was able to bring back to our discovery team.”
Stephen Krause, Senior Principal Scientist, Eisai
“Excellent networking and learning opportunity for pharma scientists.”
Matthew Kennedy, Director, Merck
“Excellent conference with a very good and diverse set of speakers and topics”
James Cassella, Chief Development Officer, Concert Pharmaceuticals